Cargando…
An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5
The mechanisms governing therapeutic resistance of the most aggressive and lethal primary brain tumor in adults, glioblastoma, have increasingly focused on tumor stem cells. These cells, protected by the periarteriolar hypoxic GSC niche, contribute to the poor efficacy of standard of care treatment...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123168/ https://www.ncbi.nlm.nih.gov/pubmed/33923334 http://dx.doi.org/10.3390/ijms22094464 |
_version_ | 1783692824863047680 |
---|---|
author | Lah Turnšek, Tamara Jiao, Xuanmao Novak, Metka Jammula, Sriharsha Cicero, Gina Ashton, Anthony W. Joyce, David Pestell, Richard G. |
author_facet | Lah Turnšek, Tamara Jiao, Xuanmao Novak, Metka Jammula, Sriharsha Cicero, Gina Ashton, Anthony W. Joyce, David Pestell, Richard G. |
author_sort | Lah Turnšek, Tamara |
collection | PubMed |
description | The mechanisms governing therapeutic resistance of the most aggressive and lethal primary brain tumor in adults, glioblastoma, have increasingly focused on tumor stem cells. These cells, protected by the periarteriolar hypoxic GSC niche, contribute to the poor efficacy of standard of care treatment of glioblastoma. Integrated proteogenomic and metabolomic analyses of glioblastoma tissues and single cells have revealed insights into the complex heterogeneity of glioblastoma and stromal cells, comprising its tumor microenvironment (TME). An additional factor, which isdriving poor therapy response is the distinct genetic drivers in each patient’s tumor, providing the rationale for a more individualized or personalized approach to treatment. We recently reported that the G protein-coupled receptor CCR5, which contributes to stem cell expansion in other cancers, is overexpressed in glioblastoma cells. Overexpression of the CCR5 ligand CCL5 (RANTES) in glioblastoma completes a potential autocrine activation loop to promote tumor proliferation and invasion. CCL5 was not expressed in glioblastoma stem cells, suggesting a need for paracrine activation of CCR5 signaling by the stromal cells. TME-associated immune cells, such as resident microglia, infiltrating macrophages, T cells, and mesenchymal stem cells, possibly release CCR5 ligands, providing heterologous signaling between stromal and glioblastoma stem cells. Herein, we review current therapies for glioblastoma, the role of CCR5 in other cancers, and the potential role for CCR5 inhibitors in the treatment of glioblastoma. |
format | Online Article Text |
id | pubmed-8123168 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81231682021-05-16 An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5 Lah Turnšek, Tamara Jiao, Xuanmao Novak, Metka Jammula, Sriharsha Cicero, Gina Ashton, Anthony W. Joyce, David Pestell, Richard G. Int J Mol Sci Review The mechanisms governing therapeutic resistance of the most aggressive and lethal primary brain tumor in adults, glioblastoma, have increasingly focused on tumor stem cells. These cells, protected by the periarteriolar hypoxic GSC niche, contribute to the poor efficacy of standard of care treatment of glioblastoma. Integrated proteogenomic and metabolomic analyses of glioblastoma tissues and single cells have revealed insights into the complex heterogeneity of glioblastoma and stromal cells, comprising its tumor microenvironment (TME). An additional factor, which isdriving poor therapy response is the distinct genetic drivers in each patient’s tumor, providing the rationale for a more individualized or personalized approach to treatment. We recently reported that the G protein-coupled receptor CCR5, which contributes to stem cell expansion in other cancers, is overexpressed in glioblastoma cells. Overexpression of the CCR5 ligand CCL5 (RANTES) in glioblastoma completes a potential autocrine activation loop to promote tumor proliferation and invasion. CCL5 was not expressed in glioblastoma stem cells, suggesting a need for paracrine activation of CCR5 signaling by the stromal cells. TME-associated immune cells, such as resident microglia, infiltrating macrophages, T cells, and mesenchymal stem cells, possibly release CCR5 ligands, providing heterologous signaling between stromal and glioblastoma stem cells. Herein, we review current therapies for glioblastoma, the role of CCR5 in other cancers, and the potential role for CCR5 inhibitors in the treatment of glioblastoma. MDPI 2021-04-24 /pmc/articles/PMC8123168/ /pubmed/33923334 http://dx.doi.org/10.3390/ijms22094464 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Lah Turnšek, Tamara Jiao, Xuanmao Novak, Metka Jammula, Sriharsha Cicero, Gina Ashton, Anthony W. Joyce, David Pestell, Richard G. An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5 |
title | An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5 |
title_full | An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5 |
title_fullStr | An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5 |
title_full_unstemmed | An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5 |
title_short | An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5 |
title_sort | update on glioblastoma biology, genetics, and current therapies: novel inhibitors of the g protein-coupled receptor ccr5 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123168/ https://www.ncbi.nlm.nih.gov/pubmed/33923334 http://dx.doi.org/10.3390/ijms22094464 |
work_keys_str_mv | AT lahturnsektamara anupdateonglioblastomabiologygeneticsandcurrenttherapiesnovelinhibitorsofthegproteincoupledreceptorccr5 AT jiaoxuanmao anupdateonglioblastomabiologygeneticsandcurrenttherapiesnovelinhibitorsofthegproteincoupledreceptorccr5 AT novakmetka anupdateonglioblastomabiologygeneticsandcurrenttherapiesnovelinhibitorsofthegproteincoupledreceptorccr5 AT jammulasriharsha anupdateonglioblastomabiologygeneticsandcurrenttherapiesnovelinhibitorsofthegproteincoupledreceptorccr5 AT cicerogina anupdateonglioblastomabiologygeneticsandcurrenttherapiesnovelinhibitorsofthegproteincoupledreceptorccr5 AT ashtonanthonyw anupdateonglioblastomabiologygeneticsandcurrenttherapiesnovelinhibitorsofthegproteincoupledreceptorccr5 AT joycedavid anupdateonglioblastomabiologygeneticsandcurrenttherapiesnovelinhibitorsofthegproteincoupledreceptorccr5 AT pestellrichardg anupdateonglioblastomabiologygeneticsandcurrenttherapiesnovelinhibitorsofthegproteincoupledreceptorccr5 AT lahturnsektamara updateonglioblastomabiologygeneticsandcurrenttherapiesnovelinhibitorsofthegproteincoupledreceptorccr5 AT jiaoxuanmao updateonglioblastomabiologygeneticsandcurrenttherapiesnovelinhibitorsofthegproteincoupledreceptorccr5 AT novakmetka updateonglioblastomabiologygeneticsandcurrenttherapiesnovelinhibitorsofthegproteincoupledreceptorccr5 AT jammulasriharsha updateonglioblastomabiologygeneticsandcurrenttherapiesnovelinhibitorsofthegproteincoupledreceptorccr5 AT cicerogina updateonglioblastomabiologygeneticsandcurrenttherapiesnovelinhibitorsofthegproteincoupledreceptorccr5 AT ashtonanthonyw updateonglioblastomabiologygeneticsandcurrenttherapiesnovelinhibitorsofthegproteincoupledreceptorccr5 AT joycedavid updateonglioblastomabiologygeneticsandcurrenttherapiesnovelinhibitorsofthegproteincoupledreceptorccr5 AT pestellrichardg updateonglioblastomabiologygeneticsandcurrenttherapiesnovelinhibitorsofthegproteincoupledreceptorccr5 |